Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986158 Monotherapy and in Combination With Ruxolitinib or Fedratinib in Myelofibrosis
NCT04817007Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2021
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of 2-(3-(3,5-dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido[3,2-b]indol-7-yl)propan-2-ol in myelofibrosis (MF), sponsored by Bristol Myers Squibb. Started Mar 2021; status: active, not recruiting.
02
Drugs
2-(3-(3,5-dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido[3,2-b]indol-7-yl)propan-2-ol
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04817007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04817007.